Outset Medical Reports Preliminary Third Quarter 2023 Financial Results

Rhea-AI Summary

Outset Medical, Inc. announces preliminary financial results for Q3 2023 and updated financial guidance for 2023.

Positive

• Preliminary revenue for Q3 was $30.4 million, a 9% increase compared to the same period last year. Outset expects revenue for 2023 to be approximately $130 million. Preliminary gross margin for Q3 was 23.6%, or 25.6% on a non-GAAP basis, compared to 16.4% in Q3 2022. Total cash was $197 million as of Sept. 30, 2023.

Negative

• The growth in the quarter was dampened by a larger-than-expected impact in the field from the recent FDA warning letter and early signs of a more cautious outlook on capital spending that is expected to continue through the fourth quarter.

Conference Call Scheduled for 4:30 p.m. ET

SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), today announced preliminary financial results for the third quarter ended Sept. 30, 2023, and provided updated financial guidance for 2023.

Preliminary revenue for the third quarter was $30.4 million, a 9% increase over revenue of $27.8 million in the third quarter of 2022. Outset now expects revenue for 2023 to be approximately $130 million. Preliminary gross margin for the third quarter was 23.6%, or 25.6% on a non-GAAP basis, compared to 16.4% on a non-GAAP basis in the third quarter of 2022. Total cash, including restricted cash, cash equivalents and short-term investments, was $197 million as of Sept. 30, 2023.

“Growth in the quarter was dampened by a larger-than-expected impact in the field from the recent FDA warning letter, and early signs of a more cautious outlook on capital spending that we see as a headwind continuing through the fourth quarter,” said Leslie Trigg, Chair and Chief Executive Officer. “Importantly, we did not see deals fall out of our pipeline and our economic value proposition remains resonant and differentiated. Our confidence around generating sustained long-term growth and reaching profitability remains high.”

Webcast and Conference Call Details

Outset will host a conference call today, Oct. 12, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its preliminary third quarter 2023 results. Those interested in listening to the conference call may do so by registering online. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.outsetmedical.com. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

The Company may report non‐GAAP results for gross profit/loss, gross margin, operating expenses, operating margins, net income/loss, basic and diluted net income/loss per share, other income/loss, and cash flows. These non-GAAP financial measures are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company’s financial measures under GAAP include stock-based compensation expense, as listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release. Management has excluded the effects of this non-cash expense item in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance and period-to-period comparisons. There are limitations related to the use of non-GAAP financial measures because they are not prepared in accordance with GAAP, may exclude significant expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non‐GAAP results are presented in the Appendix A of this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the Company’s expected results of operations, including expected revenue and gross margin for the third quarter of 2023, statements about the Company’s possible or assumed future results of operations and financial position, including expectations regarding projected revenues for 2023, gross margin, operating expenses, capital expenditures, profitability and outlook; statements regarding the Company’s overall business strategy, plans and objectives of management; the Company’s expectations regarding the market sizes and growth potential for Tablo and the total addressable market opportunities for Tablo; continued execution of the Company’s initiatives designed to expand gross margins; the Company’s ability to respond to and resolve any reports, observations or other actions by the Food and Drug Administration or other regulators in a timely and effective manner; as well as the Company’s expectations regarding the impact of macroeconomic factors on the Company, its customers and suppliers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

The financial information contained in this press release is preliminary, unaudited and subject to change or adjustment in connection with the completion of the Company’s quarter-end closing process and the preparation of its unaudited financial statements for the third quarter ended Sept. 30, 2023, which will be contained in the Company’s related Quarterly Report on Form 10-Q.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Appendix A
Outset Medical, Inc. Gross Margin – Non-GAAP (unaudited)
Reconciliation between preliminary GAAP and non-GAAP gross margin:
		Three Months Ended									Nine Months Ended
		September 30,									September 30,
		2023				2022					2023				2022
Preliminary GAAP gross margin			23.6		%		15.6		%			21.5		%		15.1		%
Preliminary stock-based compensation expense			2.0				0.8					1.4				0.6
Preliminary non-GAAP gross margin			25.6		%		16.4		%			22.9		%		15.7		%

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231012954921/en/

Investor Contact

Jim Mazzola

Outset Medical

858-342-8272

jmazzola@outsetmedical.com



Media Contact

Nicole Shannon

Director, Marketing Communications for Outset Medical

nshannon@outsetmedical.com

Source: Outset Medical, Inc.

FAQ

What were the preliminary revenue and gross margin for Q3 2023?

Preliminary revenue for Q3 was $30.4 million, a 9% increase compared to the same period last year. Preliminary gross margin for Q3 was 23.6%, or 25.6% on a non-GAAP basis, compared to 16.4% in Q3 2022.

What is the updated revenue guidance for 2023?

Outset expects revenue for 2023 to be approximately $130 million.

What was the total cash as of Sept. 30, 2023?

Total cash, including restricted cash, cash equivalents and short-term investments, was $197 million as of Sept. 30, 2023.

What factors affected the growth in the quarter?

The growth in the quarter was dampened by a larger-than-expected impact in the field from the recent FDA warning letter and early signs of a more cautious outlook on capital spending that is expected to continue through the fourth quarter.